个人介绍
胡晓春，副教授，2019年9月毕业于同济大学，获博士学位。2020年1月至2022年12月在同济大学附属东方医院从事博士后研究工作，2022年12月进入上海大学医学院工作。以（共同）第一作者或（共同）通讯作者在J. Control. Release, Small, Adv. Healthc. Mater., Chem. Commun., Acta Biomater.等权威期刊上发表SCI论文近20篇。入选上海市2020年度超级博士后，主持国家自然科学基金青年项目、中国博士后科学基金面上项目和军科委项目。
主要研究方向
1. 多肽药物的开发及应用；
2. 生物相容性多功能纳米材料的开发及应用
代表性学术成果
论文（最具代表性）
[1] X. Hu#, R. Li#, J. Liu, K. Fang, C. Dong*, S. Shi*, Engineering Dual-Responsive Prodrug-MOFs as Immunogenic Cell Death Initiator for Enhancing Cancer Immunotherapy, Adv. Healthc. Mater. (2024) 2302333.
[2] R. Li#, X. Hu#, W. Li, W. Wu, J. Xu, Y. Lin, S. Shi*, C. Dong*, Nebulized pH-Responsive Nanospray Combined with Pentoxifylline and Edaravone to Lungs for Efficient Treatments of Acute Respiratory Distress Syndrome, ACS Appl. Mater. Inter. 16(7) (2024) 8310-8320.
[3] X. Hu#, W. Zhao#, R. Li, K. Chai, F. Shang, S. Shi*, C. Dong*, A cascade nanoplatform for the regulation of the tumor microenvironment and combined cancer therapy, Nanoscale. (2023) 16314-16322.
[4] X. Hu#, R. Li#, W. Wu, K. Fang, Z. Zhu, Y. Wang, L. Zhou, M. Chen, C. Dong*, S. Shi*, A Fe(III)-porphyrin-oxaliplatin(IV) nanoplatform for enhanced ferroptosis and combined therapy, J. Control. Release 348 (2022) 660-671.
[5] X. Hu#, H. Li#, R. Li, S. Qiang, M. Chen, S. Shi*, C. Dong*, A Phase-Change Mediated Intelligent Nanoplatform for Chemo/Photothermal/Photodynamic Therapy of Cancer, Adv. Healthc. Mater. 12(5) (2022) 2202245.
[6] W. Zhao#, X. Hu#, W. Li, R. Li, J. Chen, L. Zhou, S. Qiang, W. Wu, S. Shi*, C. Dong*, M2-Like TAMs Function Reversal Contributes to Breast Cancer Eradication by Combination Dual Immune Checkpoint Blockade and Photothermal Therapy, Small 17(13) (2021) 2007051.
[7] X. Hu#, Y. Lu#, W. Zhao, M. Sun, R. Li, L. Feng, T. Yao, C. Dong*, S. Shi*, A PDA-DTC/Cu-MnO2 Nanoplatform for MR Imaging and Multi-Therapy for Triple-Negative Breast Cancer Treatment, Chem. Commun. 57(34) (2021) 4158-4161.
[8] X. Hu#, Y. Lu#, X. Shi, T. Yao, C. Dong*, S. Shi*, Integrating in Situ Formation of Nanozymes with Mesoporous Polydopamine for Combined Chemo, Photothermal and Hypoxia-Overcoming Photodynamic Therapy, Chem. Commun. 55(98) (2019) 14785-14788.
